Skip to content

US · MRM · PERSONAL PRODUCTS & SERVICES

MEDIROM Healthcare Technologies Inc. (MRM) intrinsic value and stock valuation

$0.23as of 2026-11-21 · Mkt cap 4.9M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

MEDIROM Healthcare Technologies Inc. DCF and intrinsic value

InvestorsCraft values MRM with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MRM’s statements →

MEDIROM Healthcare Technologies Inc. Graham Number

Graham Number: $20.64d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Consumer Cyclical · Personal Products & Services Tokyo, TY 135-0091 medirom.co.jp

How the business is doing

Fiscal 2018–2025, USD

Revenue
$4.04M-73.9% 5y CAGRd
20182025
Net income
$370K
20182025
Free cash flow
-$-1.9B
20182024
Total equity
$1.33B+22.1% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$4.04M$8.3B$6.83B$6.95B$5.41B
Operating income$410K-$-18.1M-$-391.58M$97M-$-470.59M
Net income$370K$148.8M$115.1M$149M-$-990.73M
EPSd$46.8K$25.4M$22.3M$27.2M-$-203.02M
Operating cash flow—-$-1.33B-$-631.74M-$-685.7M-$-557.23M
Capital expenditure—-$-564.81M-$-135.84M-$-120.74M-$-95.65M
Free cash flow—-$-1.9B-$-767.58M-$-806.44M-$-652.88M
Total assets$4.16B$8.09B$6.85B$6.75B$5.75B
Total debt$2.33B$3.96B$3.65B$3.23B$2.79B
Net debt$2.31B$3.63B$3.54B$2.63B$2.42B
Total equity$1.33B$1.19B$216M-$-59.38M-$-208.34M
Cash and short-term investments$20.1M$335.6M$132.9M$606M$377.1M
Income statement
20252024202320222021
Revenue$4.04M$8.3B$6.83B$6.95B$5.41B
Cost of revenue$140K$6.05B$5.26B$5.05B$3.99B
Gross profit$3.9M$2.25B$1.57B$1.9B$1.42B
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$3.49M$2.24B$1.96B$1.81B$1.81B
Other expenses$0.00$22.9M$0.00$0.00$75.2M
Operating expenses$3.49M$2.26B$1.96B$1.81B$1.89B
Cost and expenses$3.63M$8.32B$7.22B$6.86B$5.88B
Interest income$220K$10K$1.11M$6.07M$840K
Interest expense$390K$49.7M$36.9M$9.8M$12M
Depreciation and amortization$100K$290M$252.6M$184.1M$126.2M
Ebitda$510K$387.5M$310.1M$373.6M-$-276.29M
Operating income$410K-$-18.1M-$-391.58M$97M-$-470.59M
Total other income/expenses, net-$-30K$65.8M$412.2M$82.8M$56.1M
Income before tax$380K$47.7M$20.6M$179.8M-$-414.48M
Income tax expense$10K-$-90.48M-$-94.43M$30.8M$576.3M
Net income$370K$148.8M$115.1M$149M-$-990.73M
Weighted average shares outstanding$7.91M$5.11M$5.17M$5.47M$4.88M
Weighted average diluted shares outstanding$7.91M$5.85M$5.17M$5.47M$4.88M
Balance sheet
20252024202320222021
Cash and short-term investments$20.1M$335.6M$132.9M$606M$377.1M
Net receivables$3.53B$2B$1.23B$534.7M$312.3M
Inventory$0.00$151.6M$140M$114.1M$18.7M
Total current assets$3.57B$2.71B$1.76B$2.36B$1.38B
Property, plant and equipment, net$80.9M$2.51B$2.54B$2.38B$2.25B
Goodwill and intangible assets$16.2M$1.53B$1.41B$943.2M$991.4M
Long-term investments$235.8M$87.4M$81.5M$53M$53M
Total non-current assets$585.8M$5.38B$5.09B$4.38B$4.37B
Total assets$4.16B$8.09B$6.85B$6.75B$5.75B
Accounts payable$224.2M$1.01B$137.7M$207.6M$230.9M
Short-term debt$1.74B$1.91B$1.26B$868.9M$917.5M
Deferred revenue$37.4M$463.2M$512.1M$0.00$722.7M
Total current liabilities$2.04B$4.18B$3.56B$3.64B$3.2B
Long-term debt$596.2M$2.05B$2.39B$2.36B$1.88B
Deferred revenue, non-current$0.00$36.9M$71.1M$0.00$0.00
Total non-current liabilities$780.1M$2.72B$3.07B$3.16B$2.76B
Capital lease obligations$0.00$2.08B$2.1B$1.98B$1.88B
Total liabilities$2.82B$6.9B$6.63B$6.81B$5.96B
Common stock$20M$352.6M$20M$1.22B$1.22B
Retained earnings$594.2M$229M$80.3M-$-2.55B-$-2.69B
Accumulated other comprehensive income (loss)$3.83M$0.00$0.00$0.00$0.00
Total equity$1.33B$1.19B$216M-$-59.38M-$-208.34M
Total investments$235.8M$93.6M$82M$53.5M$59.5M
Total debt$2.33B$3.96B$3.65B$3.23B$2.79B
Net debt$2.31B$3.63B$3.54B$2.63B$2.42B
Cash flow statement
20242023202220212020
Net income$138.2M$115.1M$149M-$-990.73M-$-539.17M
Depreciation and amortization$290M$252.6M$184.1M$126.2M$62.3M
Stock-based compensation$0.00$0.00$0.00$196.9M$0.00
Change in working capital$1.97M$498.8M-$-49.94M$108.5M$267.1M
Accounts receivable$300M$580.7M-$-222.38M-$-37.02M$189.1M
Inventory-$-10.61M-$-25.87M-$-95.41M-$-2.44M-$-2.44M
Accounts payable$876.5M-$-69.88M$0.00$0.00$0.00
Net cash provided by operating activities-$-1.33B-$-631.74M-$-685.7M-$-557.23M-$-366.42M
Investments in property, plant and equipment-$-71.41M-$-135.84M-$-120.74M-$-95.65M-$-73.56M
Acquisitions, net$887.1M$584.8M-$-148M$54.2M-$-99.19M
Net cash used for investing activities$361.4M-$-328.58M$580.4M-$-83.94M-$-139.6M
Common stock issued$608.1M$0.00$0.00$0.00$1.17B
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.19B$461.2M$340.1M-$-427.95M$1.43B
Net change in cash$223.1M-$-499.11M$234.8M-$-1.07B$926.1M
Cash at end of period$329.4M$106.4M$605.5M$370.6M$1.44B
Operating cash flow-$-1.33B-$-631.74M-$-685.7M-$-557.23M-$-366.42M
Capital expenditure-$-564.81M-$-135.84M-$-120.74M-$-95.65M-$-73.56M
Free cash flow-$-1.9B-$-767.58M-$-806.44M-$-652.88M-$-439.98M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MEDIROM Healthcare Technologies Inc.

        MEDIROM Healthcare Technologies Inc. (MRM) is a Japanese company that offers comprehensive healthcare solutions, operating through two primary divisions: Relaxation Salon and Digital Preventative Healthcare. The Relaxation Salon segment oversees a network of both company-owned and franchised wellness centers, which include brands like Re.Ra.Ku and Ruam Ruam. These salons deliver various therapeutic services, such as finger-pressure bodywork, stretch therapy, posture and joint alignment, and aspects of physical therapy. They also provide specialized treatments for fatigue relief, athletic support, weight management, and reflexology. By the close of 2021, this division managed 312 such relaxation salons. The Digital Preventative Healthcare segment is dedicated to proactive health management through technology. It participates in government-mandated Specific Health Guidance programs, primarily leveraging its proprietary on-demand health monitoring smartphone application, Lav. This segment also features MOTHER Tracker for fitness tracking and provides general preventative healthcare services using its digital platforms and devices. Furthermore, MEDIROM operates the Re.Ra.Ku College in Tokyo's Odaiba area. This college offers continuous professional development for franchise owners, corporate staff, and salon employees, covering essential skills in customer service, salon management, and advanced relaxation techniques. Headquartered in Tokyo, Japan, the company was established in 2000. It adopted its current name, MEDIROM Healthcare Technologies Inc., in March 2020, having previously been known as MEDIROM Inc.

        CEO
        Kouji Eguchi
        Employees
        334
        Beta
        1.01

        Explore

        Frequently asked questions

        What is the intrinsic value of MEDIROM Healthcare Technologies Inc. (MRM)?

        MEDIROM Healthcare Technologies Inc. (MRM) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MRM undervalued?

        MRM trades at a price of $0.23 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.